Hikal Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/zzsjn12u6znx2phwb66ganef.pdf

Key Takeaways


Pharma: The Quarter's Engine

Sameer Hiremath: "quarter 3 is the financial year ending for many of our customers in both in pharma and in crop... the orders are all in place in the system, but they ask us to ship in January onwards. They don't want to take any shipments in December."

Crop Protection: Volume Up, Price Down

Sameer Hiremath: "China is definitely a long-term serious competitor, and I don't think they're going away soon. So we have to compete and we're getting involved in crop protection more on the new chemical entities and the new generation on-patent chemistry, where China is not prevalent."

CDMO: The Structural Growth Story


Animal Health & New Verticals


Geographies & Competitive Positioning

Sameer Hiremath: "Japan is already a large part of our total business, and it will grow quite substantially. And we've already got customer relationships already in play, whether it's for APIs or for intermediates on both the Pharma and on the crop side. And this is only increasing. The number of inquiries from Japan is increasing, and we stand to benefit from this. I see this very positively."

Balance Sheet & Capital Allocation

Sameer Hiremath: "debt has actually come down for the 6 months... it's a very, very comfortable position, and we don't see any significant increase in this."

Guidance & Commitments

CommitmentSpecificsTimeline
Pharma momentumExpect same momentum to continue; Q3 may see suppressed growth but Q4 will bounce back; H2 overall in the same lineH2 FY25
CDMO commercial suppliesCommercial supplies for an innovator customerH2 CY25
Animal health commercializationValidated products submitted for registration, then final commercializationNext few quarters
NCE commercializationTwo novel NCEs in Phase 3 trialsNext 2–3 years
Specialized ingredients peak revenueProjects progressing wellUpcoming 2–3 years
Crop Protection margin improvementMargin profile to improve as capacity ramp-up takes placeH2 FY26, if not H1 FY26
Debt rangeDebt expected close to ₹800 crores for current year; ₹130 crores repayment next year; range maintained with capex borrowingFY25 / FY26
R&D spendContinue to allocate ~4–5% of revenueOngoing
H2 vs H1H2 expected to be stronger than H1FY25
FY26 vs FY25Expect growth in both Pharma revenue and marginsFY26
CDMO share of Pharma revenueExpect CDMO percentage to increase furtherGoing forward
Animal health validation completionFinish validation of innovator customer product portfolio, then start other productsNext 1–2 quarters

Key Metrics

MetricQ2 FY25
Revenue₹453 cr, +29% QoQ and +29% YoY
EBITDA₹75 cr, +30% QoQ and +30% YoY
EBITDA margin16.5%, up from 13.2% in Q2 FY24
H1 FY25 revenue₹860 cr, +4% QoQ and +23% YoY
H1 FY25 EBITDA₹133 cr
H1 FY25 EBITDA margin15.5%
Pharma revenue₹294 cr, EBIT ₹40 cr
Pharma EBIT margin change+934 bps YoY and +994 bps QoQ
Pharma value growth+9% (Q2), volume growth +3.5%
Pharma value growth (H1)+6%, volume growth +5%
Crop Protection revenue₹159 cr, EBIT ₹8 cr, EBIT margin 5%
Crop Protection value growth-4% (Q2), volume growth +22%
Crop Protection value growth (H1)+2%, volume growth +45%
Pharma capacity utilization75%–80%
Crop Protection capacity utilization55%–60%
CDMO share of Pharma revenue~40%, up over 10 percentage points
Working capital reduction₹50 cr
Debt expected (FY25)~₹800 cr, with ₹130 cr repayment due in FY26
R&D spend~4%–5% of revenue
Animal health products validated6 products, registrations expected in 12–18 months
Crop Protection CDMO pipeline7 projects, 2–3 closer to 3–4 year timeline
Customer auditsAt least 50% above last year (rough estimate)